Bruker Corporation announced that its Board of Directors has added Jack J. Phillips to serve on its board of directors, effective as of January 1st, 2026. Mr. Phillips is a senior healthcare industry executive with over 30 years of leadership experience in the diagnostics industry.
EyeYon Medical Ltd., a global leader in ophthalmic innovation, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to initiate a U.S. clinical study of EndoArt®, the world's first synthetic endothelial layer for the treatment of chronic corneal edema. EndoArt® is currently designated by the FDA as a Breakthrough Device.
Wingderm® announces that its Renuva 1550nm non-ablative fractional laser system has obtained MDR certification in the European Union, marking a significant regulatory milestone for the device within the EU market.
The premier mobile IV therapy company drew over 200 attendees to its November wellness and education event featuring elite wellness experts, IVDRIPS activations, and glam experiences.
Medit, a global leader in 3D intraoral scanning solutions, and OraQ, a pioneer in AI-powered clinical intelligence, today announced a strategic partnership designed to accelerate the integration of artificial intelligence and real-time clinical insight into digital dentistry.
Rockwell Medical, Inc. a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, announced that Heather Hunter was promoted to Chief Operating Officer, and will continue to report to the Company's President and CEO, Dr. Mark Strobeck.
Kardium, a private medical device company that’s advancing the way the world treats atrial fibrillation (AF), announced the successful completion of the first commercial procedures using its integrated mapping and ablation system, the Globe Pulsed Field System, following recent approval from the U.S. Food and Drug Administration (FDA).
RefleXion Medical, an external‑beam theranostic oncology company, announced first results from the PREMIER Registry (NCT05406167) evaluating its SCINTIX® biology-guided radiotherapy, or BgRT, platform in patients with lung and bone tumors. The findings, presented at the 2025 ASTRO Annual Meeting, showed local control of 100 percent at nine months post-treatment with no reported Grade 2 or higher adverse events. The data represent the first prospective, multi-institutional evidence of SCINTIX therapy’s clinical impact.
Phraxis, Inc., a leader in vascular access innovation, announced the successful completion of the first commercial case using the EndoForce™ Anastomotic Connector, marking a historic milestone in the treatment of dialysis patients worldwide.
Imperative Care, Inc announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Symphony® Thrombectomy System to treat pulmonary embolism (PE), a life-threatening condition caused by blood clots blocking an artery in the lungs.